Leading from more than 20 years of experience in Raman spectroscopy and more than 12 years of research on Raman spectroscopy for diagnosing neurodegenerative diseases, Brainalyze have developed a unique solution that is quick, accurate, and effective even at the pre-manifest stages.

Through the development of a spectroscopy method initially used to distinguish between different types of bacteria, Brainalyze have devised a new multi-laser method that creates a light-based fingerprint from biomarkers within a blood sample. This ‘optical fingerprint’ can be used to distinguish between different causes of dementia as it encompasses holistic and unbiased information rather than a single protein. Data from pre-clinical trials on patient samples have found this method to be accurate in 93% of cases for identifying Alzheimer’s, with similar results for other neurodegenerative diseases and for tracking Huntington’s disease